Enhanced sensitivity to quipazine in the genetically dystonic rat (dt).
Both normal and genetically dystonic (dt) rats show a high-frequency forepaw tremor in response to systemic administration of the serotonin (5-HT) agonist quipazine at 8 days of age. The response declines with age in normal, but not dystonic, rats. By 16 days of age and after the development of a generalized movement disorder, the dystonic rat exhibits enhanced sensitivity to the tremorogenic effects of the drug in comparison with normal rats. Tremor was blocked by pretreatment with ketanserin, suggesting that it is mediated by 5-HT2 receptors. The dystonic rat has previously been shown to be insensitive to the tremorogenic effects of harmaline, a drug presumed to act indirectly through serotonergic neurons. This finding, coupled with the increased sensitivity to quipazine, suggests the presence of an abnormality in serotonergic systems in the mutants. Since there is evidence of abnormality in the olivo-cerebellar system in the dystonic rat, the alternative hypothesis that a nonserotonergic defect in the olivo-cerebellar system accounts for both the failure of behavioral response to harmaline and the persistent expression of a response to quipazine is also discussed.